Takeda has been selected for the fifth consecutive year for Dow Jones Sustainability Asia Pacific Index

Osaka, Japan, September 25, 2014 – Takeda Pharmaceutical Company Limited (“Takeda”) announced today that it has been selected for the fifth consecutive year for the Dow Jones Sustainability Asia Pacific Index (DJSI Asia Pacific), the Asia Pacific version of the Dow Jones Sustainability Indexes (DJSI), which is one of the world’s premier indices for Socially Responsible Investment (SRI)*.

Provided by S&P Dow Jones Indices LLC of the United States, DJSI is a leading SRI index which assesses and selects leading sustainability-driven companies in terms of economic, environmental, and social criteria, and serves as one of the most important indices for investors who take into consideration the corporate social responsibility (CSR) initiatives of each company. Specifically designed for companies in the developed Asia Pacific markets including Japan, the DJSI Asia Pacific has captured the 148 companies, including 65 Japanese companies, which are leading the way in terms of sustainability among the 600 companies in the region.

For inclusion in the DJSI Asia Pacific, Dow Jones assesses companies based on questionnaire responses, annual reports from each company and company information on media. Takeda has been included in the DJSI Asia Pacific for the fourth consecutive year for its outstanding performance based on the three criteria above.

In addition to DJSI Asia Pacific, Takeda has also been included in the FTSE4Good Global Index by the FTSE Group and the Ethibel Excellence Investment Register complied by Forum Ethibel of Belgium, and the Morningstar Socially Responsible Investment Index (MS-SRI) compiled by Morningstar Japan K.K..

As a pharmaceutical company that is related to people’s lives, Takeda will remain committed to the fulfillment of its social responsibility in response to the demands of global society. In this way, Takeda further builds its corporate value, while also remaining focused on our mission of “striving towards better health for people worldwide through leading innovation in medicine.”

* Making investment decisions based on criteria that take into account whether a company is fulfilling its social responsibility from social, ethical, environmental, and other perspectives, in addition to the findings of financial analysis

###